SCHEMBL4034681

SCHEMBL4034681

CCOC(=O)CSC(C)(C)C(=O)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
MGAM O43451 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
ALDH1A1 P00352 10/20 0.39
TRPA1 O75762 1/20 0.39
CYP1A2 P05177 2/20 0.38
HTT P42858 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SOAT1 P35610 1/20 0.37
HSD17B10 Q99714 3/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RAB9A P51151 1/20 0.36
TSHR P16473 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8354123 0.79 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL11796653 0.74 GAA (0.43) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL10136452 0.73 CYP1A2 (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL11738074 0.73 GAA (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL284061 0.69 GAA (0.57) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL8544332 0.69 GAA (0.57) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL12340598 0.69 LMNA (0.35) ALDH1A1CYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL31567720 0.69 GAA (0.38) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL27437072 0.68 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL891469 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687301-B1 THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES LEIBNIZ INST FUER PFLANZENBIOC (DE) 2009-05-13 EP claimed
US-7381743-B2 Macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2008-06-03 US disclosed
US-7381743-B2 Macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2008-06-03 US disclosed
US-20070105905-A1 Novel macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2007-05-10 US disclosed
US-20070105905-A1 Novel macrocycles for the treatment of cancer LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105905-A1 Novel macrocycles for the treatment of cancer HCCS, FOLR1, AURKAIP1 GAA 439/4885MGAM 2529/4885SI 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.